Clinical Trials Browser

Phase 2 × Neoplasms × niraparib × Clear all

NCT01042379 2026-03-13

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04341181 2025-07-25

ProTarget

Phase 2 Recruiting

Neoplasms

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Phase 2 Completed

53 enrolled 35 charts

Neoplasms